Summary & Overview
HCPCS Level II J1655: Injection, tinzaparin sodium 1000 IU
HCPCS Level II code J1655 denotes injection of tinzaparin sodium, 1000 IU, an anticoagulant used for prevention and treatment of thromboembolic events. Nationally, biologic and anticoagulant injectables are notable for site-of-service variation, coverage nuances across public and commercial payers, and frequent implications for prior authorization and drug administration billing. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, the typical clinical and service contexts for administration, and an overview of payer coverage patterns and billing considerations. The publication highlights benchmarks for utilization and payment where available, common billing modifiers and service-line placement, and relevant policy considerations that affect reimbursement and claim adjudication for injectable anticoagulants. Data not available in the input is identified where applicable, and the report focuses on national coverage and administrative issues rather than state-specific rules.
Billing Code Overview
HCPCS Level II code J1655 represents an injection of tinzaparin sodium, 1000 IU. The service is an anticoagulant injection delivered as a medication administration procedure. Typical site of service for this injectable medication includes hospital outpatient departments, physician offices, and home health or infusion settings when administered by a clinician or a qualified caregiver.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J1655 (injection, tinzaparin sodium, 1000 IU) is an adult or geriatric patient requiring therapeutic or prophylactic anticoagulation in the outpatient or inpatient setting. Common scenarios include treatment of acute venous thromboembolism (deep vein thrombosis or pulmonary embolism), prophylaxis of venous thromboembolism after orthopedic surgery or prolonged immobilization, and anticoagulation for medically ill patients at elevated thrombotic risk when low molecular weight heparin is indicated.
Workflow: A clinician (hospitalist, hematologist, orthopedic surgeon, or ambulatory anticoagulation clinic nurse) evaluates the patient, confirms indication and weight-based dosing, verifies renal function and bleeding risk, documents informed consent and the anticoagulation plan in the medical record, and orders the medication in the electronic medical record. Pharmacy prepares the prefilled syringe or vial and verifies dose. A licensed nurse or trained clinician administers the subcutaneous injection (or supervises patient self-administration teaching), documents lot number and site, monitors for immediate adverse reaction, and schedules follow-up monitoring (anti-Xa level if indicated, CBC, renal function). Billing for the drug is reported with HCPCS Level II code J1655 for each 1000 IU unit administered. Appropriate modifier use reflects circumstances such as unusual effort, anesthesia services, or patient status modifications.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|